A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal

NCT05168436 | Completed

• 1 other identifier: CA209-9W6
• Study Type: observational
• Target: 105
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.

Conditions

Renal Cell Carcinoma

Keywords

OPDIVO®; Nivolumab; Preference; RCC

Outcome Measures

Primary Outcomes (2)

• Utility: Renal cell carcinoma (RCC) participants' preferences

  Utility (preference score) derived for a treatment alternative choice (scenario)

  At Baseline

• Utility: Oncologists' preferences

  Utility (preference score) derived for a treatment alternative choice (scenario)

  At Baseline

Secondary Outcomes (23)

• Distribution of socio-demographic characteristics of Renal cell carcinoma (RCC) participants: Age

  At Baseline

• Distribution of clinical characteristics of RCC participants: Time since RCC diagnosis

  At Baseline

• Distribution of socio-demographic characteristics of RCC participants: Place of residence

  At Baseline

• Distribution of socio-demographic characteristics of RCC participants: Gender

  At Baseline

• Distribution of socio-demographic characteristics of RCC participants: Economic status (income)

  At Baseline

Study Arms (2)

Cohort 1

Participants with renal cell carcinoma (RCC) treated with nivolumab

Cohort 2

Oncologists with expertise in renal cancer from Spain and Portugal

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Participants with diagnosis of Renal Cell Carcinoma (RCC) from a total of eight to eleven hospitals (6-8 located in Spain and 2-3 in Portugal) and oncologists with expertise in renal cancer from Spain and Portugal will participate in the study.

You may qualify if:

• The oncologist is currently working in a Spanish or Portuguese public hospital.
• The oncologist has at least 2 years of experience in the management of participants with Renal Cell Carcinoma (RCC).
• The oncologist has agreed to participate in the study.
• The participant has received or is currently receiving pharmacological treatment for RCC;
• The participant has provided the informed consent to participate in the study.
• The participant must be able to read, understand and complete the survey instrument according to the judgment of the responsible physician.

You may not qualify if:

• Not applicable

Sponsors & Collaborators

• Bristol-Myers Squibb: lead

Study Sites (1)

Local Institution

Castellon, 12071, Spain

Location

Related Links

• BMS Clinical Trial Information
• Investigator Inquiry Form
• FDA Safety Alerts and Recalls

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Kidney Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Study Officials

• Bristol-Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2021
• First Posted: December 23, 2021
• Study Start: August 5, 2019
• Primary Completion: July 13, 2020
• Study Completion: July 13, 2020
• Last Updated: December 23, 2021

Record last verified: 2021-12

Locations

ES (1)